Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:IFRX NASDAQ:RGNX NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$12.50-5.4%$10.95$0.88▼$17.25$528.80M1.05255,080 shs130,572 shsIFRXInflaRx$1.74+0.6%$2.05$0.74▼$2.95$125.07M2.441.31 million shs823,297 shsRGNXREGENXBIO$9.73-5.1%$9.26$5.45▼$16.19$529.90M0.92.56 million shs974,282 shsZURAZura Bio$5.23-1.1%$4.55$1.35▼$7.44$501.92M-0.031.49 million shs366,206 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye-5.45%+8.41%+13.74%-15.54%+750.34%IFRXInflaRx+0.58%-6.20%-10.08%+17.57%+102.61%RGNXREGENXBIO-5.07%-1.62%-2.41%+11.07%+7.04%ZURAZura Bio-1.13%-4.04%+22.77%-2.79%+209.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$12.50-5.4%$10.95$0.88▼$17.25$528.80M1.05255,080 shs130,572 shsIFRXInflaRx$1.74+0.6%$2.05$0.74▼$2.95$125.07M2.441.31 million shs823,297 shsRGNXREGENXBIO$9.73-5.1%$9.26$5.45▼$16.19$529.90M0.92.56 million shs974,282 shsZURAZura Bio$5.23-1.1%$4.55$1.35▼$7.44$501.92M-0.031.49 million shs366,206 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye-5.45%+8.41%+13.74%-15.54%+750.34%IFRXInflaRx+0.58%-6.20%-10.08%+17.57%+102.61%RGNXREGENXBIO-5.07%-1.62%-2.41%+11.07%+7.04%ZURAZura Bio-1.13%-4.04%+22.77%-2.79%+209.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.67Moderate Buy$24.2594.00% UpsideIFRXInflaRx 2.71Moderate Buy$7.00302.30% UpsideRGNXREGENXBIO 2.62Moderate Buy$23.82144.79% UpsideZURAZura Bio 2.71Moderate Buy$10.75105.54% UpsideCurrent Analyst Ratings BreakdownLatest IFRX, RGNX, ANL, and ZURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026ANLAdlai Nortye Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/14/2026RGNXREGENXBIO Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/8/2026ZURAZura Bio William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform7/6/2026ZURAZura Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/1/2026RGNXREGENXBIO HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.007/1/2026ZURAZura Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$15.006/24/2026IFRXInflaRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026RGNXREGENXBIO HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.006/22/2026RGNXREGENXBIO Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$17.00 ➝ $18.006/22/2026RGNXREGENXBIO Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$27.00 ➝ $32.006/22/2026ANLAdlai Nortye Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M100.00N/AN/A($0.21) per share-59.52IFRXInflaRx$29.33K4,288.63N/AN/A$0.65 per share2.68RGNXREGENXBIO$170.44M2.95N/AN/A$2.03 per share4.79ZURAZura BioN/AN/AN/AN/A$1.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$35.53MN/AN/AN/AN/AN/AN/AN/A8/6/2026 (Estimated)IFRXInflaRx-$51.63M-$0.71N/AN/AN/AN/A-88.30%-65.77%8/6/2026 (Estimated)RGNXREGENXBIO-$193.88M-$5.60N/AN/AN/A-330.23%-232.50%-61.02%8/6/2026 (Estimated)ZURAZura Bio-$99.35M-$1.09N/AN/AN/AN/A-55.74%-48.07%8/13/2026 (Estimated)Latest IFRX, RGNX, ANL, and ZURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026ZURAZura Bio-$0.20N/AN/AN/AN/AN/A8/6/2026Q2 2026ANLAdlai Nortye-$0.1333N/AN/AN/A$3.95 millionN/A8/6/2026Q2 2026IFRXInflaRx-$0.08N/AN/AN/A$0.01 millionN/A8/6/2026Q2 2026RGNXREGENXBIO$0.12N/AN/AN/A$96.46 millionN/A5/14/2026Q1 2026RGNXREGENXBIO-$1.36-$1.72-$0.36-$1.72$25.84 million$6.39 million5/7/2026Q1 2026ZURAZura Bio-$0.17-$0.22-$0.05-$0.22N/AN/A5/6/2026Q1 2026IFRXInflaRx-$0.17-$0.09+$0.08-$0.09$0.01 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai NortyeN/A0.650.65IFRXInflaRxN/A4.164.16RGNXREGENXBION/A2.622.62ZURAZura BioN/A19.3319.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%IFRXInflaRx42.39%RGNXREGENXBIO88.08%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/AIFRXInflaRx16.30%RGNXREGENXBIO14.22%ZURAZura Bio12.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12740.00 millionN/ANot OptionableIFRXInflaRx6072.29 million60.51 millionOptionableRGNXREGENXBIO37051.70 million44.35 millionOptionableZURAZura Bio394.88 million83.14 millionOptionableIFRX, RGNX, ANL, and ZURA HeadlinesRecent News About These CompaniesZura Bio Limited $ZURA Shares Acquired by Affinity Asset Advisors LLCJuly 25 at 3:12 AM | marketbeat.comSiren L.L.C. Acquires 2,434,866 Shares of Zura Bio Limited $ZURAJuly 24 at 6:16 AM | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Moderate Buy" from AnalystsJuly 23 at 4:13 AM | marketbeat.comZura Bio (NASDAQ:ZURA) Stock Price Up 5.3% - Time to Buy?July 17, 2026 | marketbeat.comWilliam Blair Starts Zura Bio (ZURA) at OutperformJuly 14, 2026 | uk.finance.yahoo.comZura Bio (NASDAQ:ZURA) Stock Rating Lowered by Wall Street ZenJuly 12, 2026 | marketbeat.comLicensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonistJuly 9, 2026 | businesswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Zura Bio (ZURA)July 9, 2026 | theglobeandmail.comZura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab ProgramJune 29, 2026 | finance.yahoo.comZura Bio (ZURA) Gets a Buy from OppenheimerJune 13, 2026 | theglobeandmail.comHere's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn SituationJune 3, 2026 | finance.yahoo.comZura Bio Announces Board Resignation, Governance Stability AffirmedMay 22, 2026 | tipranks.comAnalysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Zura Bio (ZURA)May 11, 2026 | theglobeandmail.comZura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | businesswire.comZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | businesswire.comZura Bio Limited Class AApril 24, 2026 | edition.cnn.comOne Zura Bio Insider Raised Their Stake In The Previous YearApril 23, 2026 | finance.yahoo.comPiper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA)April 16, 2026 | theglobeandmail.comZura Bio: Momentum Is Real, But TibuSHIELD Needs To DeliverMarch 31, 2026 | seekingalpha.comZura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesMarch 19, 2026 | businesswire.comZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World CongressMarch 5, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 20263 Top Financial Institutions Announce Over $70 Billion in Share RepurchasesBy Leo Miller | June 30, 2026Buyback Boom: These 3 Companies Are Betting Billions on Their Own StocksBy Jessica Mitacek | July 20, 2026Has Broadcom Become Too Expensive for Its AI Story?By Sam Quirke | July 17, 20265 Dividend Kings to Buy in July with Irresistible Value and YieldBy Thomas Hughes | July 8, 2026IFRX, RGNX, ANL, and ZURA Company DescriptionsAdlai Nortye NASDAQ:ANL$12.50 -0.72 (-5.45%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$12.05 -0.45 (-3.63%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.InflaRx NASDAQ:IFRX$1.74 +0.01 (+0.58%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.74 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.REGENXBIO NASDAQ:RGNX$9.73 -0.52 (-5.07%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$9.70 -0.03 (-0.31%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Zura Bio NASDAQ:ZURA$5.23 -0.06 (-1.13%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.22 -0.01 (-0.10%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
